ASO Author Reflections: APRI + ALBI: A Novel Tool for Estimating Chemotherapy-Associated Liver Injury in Patients with Colorectal Cancer Liver Metastasis Undergoing Liver Resection

Excerpt

Within the past decade, the management of patients treated for colorectal cancer liver metastasis changed rapidly and evolved to be one of the most prominent fields within surgical oncology. Perioperative chemotherapy improves the outcome of both resectable and initially unresectable colorectal cancer liver metastasis.1 Despite the benefit in terms of oncologic outcome, chemotherapy-associated liver injury is frequently observed in these patients and shown to have a significant negative impact on the postoperative clinical outcome after liver resection.2^,3 This is of specific relevance because postoperative morbidity significantly affects the overall oncologic outcome of colorectal cancer liver metastasis. Yet, to date, no valid tool exists to assess chemotherapy-associated liver injury. Therefore, preoperative risk stratification after neoadjuvant chemotherapy remains a difficult task for clinicians worldwide. …